bosentan anhydrous has been researched along with Chronic Disease in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (14.29) | 18.2507 |
| 2000's | 23 (54.76) | 29.6817 |
| 2010's | 12 (28.57) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Kelder, JC; Mager, JJ; Post, MC; Snijder, RJ; Ten Klooster, L; van Thor, MCJ | 1 |
| Halank, M; Held, M; Igarashi, T; Kunihara, T; Nomura, R; Sata, F; Schäfers, HJ; Wilkens, H | 1 |
| Caspi, A; DeMets, D; Kiowski, W; Kobrin, I; Krum, H; Massie, BM; McMurray, JJV; Packer, M; Petrie, MC; Pratt, CM; Roux, S; Swedberg, K | 1 |
| Gaine, SP; Murphy, DM; Murphy, DT; Murray, JG | 1 |
| Cannon, JE; Pepke-Zaba, J | 1 |
| Kario, K; Nishikawa-Takahashi, M; Ueno, S | 1 |
| Cebotari, S; Hoeper, MM; Madani, MM; Meyer, B; Nakanishi, N; Rubin, LJ | 1 |
| Lejnieks, A; Lesina, K; Rudzitis, A; Sablinskis, K; Skride, A | 1 |
| Channick, R; Jais, X; Pepke-Zaba, J | 1 |
| Gewitz, M; Krishnan, S; Krishnan, U | 1 |
| Arora, R; Jawad, E | 1 |
| D'Armini, AM; Delcroix, M; Ghofrani, HA; Hoeper, MM; Jaïs, X; Jansa, P; Lang, IM; Mayer, E; Morganti, A; Pepke-Zaba, J; Perchenet, L; Rubin, LJ; Simonneau, G; Torbicki, A | 1 |
| Cassandro, R; Confalonieri, M; Harari, S; Kodric, M; Piattella, M; Potena, A; Scarda, A; Scarduelli, C; Vassallo, FG | 1 |
| Kostrubiec, M; Pedowska-Włoszek, J; Pruszczyk, P | 1 |
| Confalonieri, M; Kodric, M; Longo, C; Vassallo, FG | 1 |
| Agnelli, G; Becattini, C; Busti, C; Gennarini, S; Manina, G | 1 |
| Kähler, CM | 1 |
| Bauleo, C; Catapano, G; Formichi, B; Genovesi, D; Giuntini, C; Mannucci, F; Marini, C; Michelassi, C; Monti, S; Prediletto, R | 1 |
| Aoki, T; Fukumoto, Y; Miura, Y; Miyamichi-Yamamoto, S; Nochioka, K; Satoh, K; Shimokawa, H; Sugimura, K; Tatebe, S | 1 |
| Dinger, B; Fidone, S; He, L; Liu, X; Stensaas, L | 1 |
| Goto, K; Miyauchi, T | 1 |
| Piuhola, J; Ruskoaho, H; Szokodi, I | 1 |
| Chin, KM; Kim, NH; Rubin, LJ | 1 |
| Apostolopoulou, SC; Cokkinos, DV; Manginas, A; Rammos, S | 1 |
| Del Rio, R; Iturriaga, R; Rey, S | 1 |
| Hammerschmidt, S; Pankau, H; Seyfarth, HJ; Winkler, J; Wirtz, H | 1 |
| Christopoulos, A; Kourouklis, S; Kyriakides, ZS; Liagkas, K; Paradellis, G | 1 |
| Casset-Sedon, D; Cosnay, P; Maillot, F; Pierre, B; Regina, S; Sitbon, O | 1 |
| Alonso-Pulpón Rivera, L; Gómez Bueno, M; González González, M; Moñivas Palomero, V; Ortiz Uribe, JC; Segovia Cubero, J | 1 |
| Auger, WR; Fedullo, PF; Kerr, KM; Kim, NH; Test, VJ | 1 |
| Brentjens, TE; Bulman, W; Coyle, CM; Dickstein, ML; Emond, J; Horn, EM; Kawut, SM; Wilt, JS | 1 |
| Aubert, JD; Domenighetti, G; Fischler, M; Geiser, T; Huber, L; Rochat, T; Speich, R; Treder, U; Ulrich, S | 1 |
| Adnot, S; Clozel, M; Eddahibi, S; Levame, M; Raffestin, B | 1 |
| Clozel, JP; Clozel, M; Hess, P; Löffler, BM; Maire, JP; Teerlink, JR | 1 |
| Bertel, O; Kiowski, W; Sütsch, G | 1 |
| Comoy, E; Compagnon, P; Derumeaux, G; Henry, JP; Hogie, M; Lallemand, F; Letac, B; Macé, B; Mulder, P; Richard, V; Thuillez, C | 1 |
| Abbott, BM; Bertelsen, DL; DeSiato, MA; Rumsey, WL | 1 |
| Bertel, O; Christen, S; Hunziker, P; Kim, JH; Kiowski, W; Rickenbacher, P; Strobel, W; Sütsch, G; Yan, XW | 1 |
| Channick, RN; Chiles, PG; Kim, H; Konopka, RG; Marsh, JJ; Morris, TA; Pedersen, CA; Yung, GL | 1 |
| Abraham, WT; Lamba, S; Suresh, DP | 1 |
| Bertel, O; Kiowski, W; Oechslin, E; Sütsch, G | 1 |
| Cheng, TO | 1 |
13 review(s) available for bosentan anhydrous and Chronic Disease
| Article | Year |
|---|---|
Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials.
Topics: Aged; Australia; Bosentan; Cause of Death; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Endothelin Receptor Antagonists; Europe; Female; Heart Failure; Humans; Internationality; Kaplan-Meier Estimate; Male; Middle Aged; Morbidity; North America; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Sulfonamides; Survival Analysis; Time Factors; Treatment Outcome | 2017 |
Is distal chronic thromboembolic pulmonary hypertension treatable with PAH targeted drugs?
Topics: Antihypertensive Agents; Bosentan; Chronic Disease; Compassionate Use Trials; Endarterectomy; Humans; Hypertension, Pulmonary; Piperazines; Pulmonary Embolism; Purines; Pyrazoles; Pyrimidines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2013 |
Chronic thromboembolic pulmonary hypertension.
Topics: Angioplasty, Balloon; Bosentan; Chronic Disease; Endarterectomy; Endothelin Receptor Antagonists; Enzyme Activators; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Embolism; Purines; Pyrazoles; Pyrimidines; Sildenafil Citrate; Sulfonamides; Thromboembolism | 2014 |
Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension.
Topics: Bosentan; Chronic Disease; Comorbidity; Endarterectomy; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Pulmonary Embolism; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention; Sulfonamides | 2016 |
Chronic stable angina pectoris.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetanilides; Angina Pectoris; Antihypertensive Agents; Benzazepines; Bosentan; Chronic Disease; Counterpulsation; Cyclic Nucleotide-Gated Cation Channels; Exercise Test; Heart Murmurs; Humans; Ivabradine; Myocardial Contraction; Myocardial Ischemia; Myocardial Revascularization; Myocardium; Nicorandil; Oxygen Consumption; Perhexiline; Piperazines; Protein Kinase Inhibitors; Ranolazine; Sulfonamides; Trimetazidine; Vasodilator Agents | 2008 |
[Potential role of endothelin in patients with acute pulmonary embolism and chronic thromboembolic pulmonary hypertension].
Topics: Acute Disease; Antihypertensive Agents; Bosentan; Chronic Disease; Endothelins; Humans; Hypertension, Pulmonary; Pulmonary Embolism; Sulfonamides | 2009 |
Bosentan for chronic thromboembolic pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Chronic Disease; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Sulfonamides; Thromboembolism | 2009 |
Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis.
Topics: Antihypertensive Agents; Bosentan; Case-Control Studies; Chronic Disease; Cohort Studies; Double-Blind Method; Hemodynamics; Humans; Hypertension; Hypertension, Pulmonary; Pulmonary Embolism; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome; Vascular Resistance | 2010 |
[New expansion of endothelin research: perspectives for clinical application of endothelin-receptor antagonists].
Topics: Animals; Bosentan; Cardiovascular Diseases; Chronic Disease; Clinical Trials as Topic; Disease Models, Animal; Drug Design; Endothelin Receptor Antagonists; Endothelin-1; Growth Substances; Humans; Mitogens; Receptors, Endothelin; Sulfonamides; Vasoconstriction | 2003 |
The right ventricle in pulmonary hypertension.
Topics: Bosentan; Cardiac Output; Chronic Disease; Drug Therapy, Combination; Epoprostenol; Female; Heart Failure; Heart Function Tests; Heart Ventricles; Humans; Hypertension, Pulmonary; Male; Prognosis; Risk Assessment; Severity of Illness Index; Stroke Volume; Sulfonamides; Survival Rate; Treatment Outcome; Ventricular Dysfunction, Right; Ventricular Function | 2005 |
Chronic thromboembolic pulmonary hypertension.
Topics: Antibodies, Antiphospholipid; Bosentan; Cardiac Catheterization; Chronic Disease; Endarterectomy; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Physical Exertion; Pulmonary Embolism; Risk Factors; Sulfonamides; Thrombectomy | 2007 |
New developments in heart failure: role of endothelin and the use of endothelin receptor antagonists.
Topics: Bosentan; Carboxylic Acids; Chronic Disease; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Humans; Indans; Peptides, Cyclic; Prognosis; Pyridines; Pyrimidines; Receptors, Endothelin; Sulfonamides; Treatment Outcome | 2000 |
Hemodynamic effects of bosentan in patients with chronic heart failure.
Topics: Bosentan; Chronic Disease; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Hemodynamics; Humans; Receptors, Endothelin; Sulfonamides | 2001 |
8 trial(s) available for bosentan anhydrous and Chronic Disease
| Article | Year |
|---|---|
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Topics: Antihypertensive Agents; Bosentan; Chronic Disease; Disease Progression; Double-Blind Method; Endarterectomy; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prognosis; Severity of Illness Index; Sulfonamides; Thromboembolism | 2008 |
Bosentan for patients with chronic thromboembolic pulmonary hypertension.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Bosentan; Chronic Disease; Diuretics; Drug Therapy, Combination; Dyspnea; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Sulfonamides; Treatment Outcome; Walking; Young Adult | 2009 |
Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension.
Topics: Aged; Angioplasty; Antihypertensive Agents; Bosentan; Chronic Disease; Combined Modality Therapy; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Piperazines; Prognosis; Prospective Studies; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2012 |
Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Chronic Disease; Exercise; Exercise Tolerance; Female; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Oximetry; Sulfonamides; Treatment Outcome | 2005 |
[Role of bosentan in patients with chronic venous thromboembolic pulmonary hypertension].
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Chronic Disease; Data Interpretation, Statistical; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Embolism; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome | 2007 |
Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonar
Topics: Aged; Antihypertensive Agents; Bosentan; Chronic Disease; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Health Status Indicators; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Pulmonary Embolism; Quality of Life; Severity of Illness Index; Sulfonamides | 2007 |
Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Bosentan; Chronic Disease; Double-Blind Method; Endothelin Receptor Antagonists; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Receptor, Endothelin A; Sulfonamides; Time Factors; Vascular Resistance | 1997 |
Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.
Topics: Administration, Oral; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Bosentan; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prospective Studies; Receptor, Endothelin A; Sulfonamides; Treatment Outcome | 1998 |
21 other study(ies) available for bosentan anhydrous and Chronic Disease
| Article | Year |
|---|---|
Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
Topics: Aged; Bosentan; Chronic Disease; Drug Therapy, Combination; Endarterectomy; Endothelin Receptor Antagonists; Enzyme Activators; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Phosphodiesterase 5 Inhibitors; Pulmonary Embolism; Pyrazoles; Pyrimidines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Survival Rate; Walk Test | 2019 |
Haemodynamic benefit of bridging use of bosentan prior to pulmonary endarterectomy.
Topics: Bosentan; Chronic Disease; Endarterectomy; Hemodynamics; Humans; Hypertension, Pulmonary; Pulmonary Artery; Pulmonary Embolism; Treatment Outcome | 2021 |
Case 1: chronic thromboembolic pulmonary hypertension (CTEPH).
Topics: Adult; Anticoagulants; Antihypertensive Agents; Bosentan; Chronic Disease; Diuretics; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Male; Pulmonary Embolism; Sulfonamides; Tomography, X-Ray Computed; Warfarin | 2013 |
Long-term advanced therapy with bosentan improves symptoms and prevents deterioration of inoperable chronic thromboembolic pulmonary hypertension.
Topics: Asian People; Bosentan; Chronic Disease; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Japan; Male; Middle Aged; Pulmonary Embolism; Sulfonamides; Time Factors | 2014 |
First data from Latvian chronic thromboembolic pulmonary hypertension registry.
Topics: Adult; Age Distribution; Aged; Anticoagulants; Bosentan; Chronic Disease; Female; Humans; Hypertension, Pulmonary; Incidence; Latvia; Male; Middle Aged; Phenylpropionates; Prevalence; Pulmonary Embolism; Pyrazoles; Pyridazines; Pyridones; Registries; Rivaroxaban; Sex Distribution; Sildenafil Citrate; Sulfonamides; Vasodilator Agents; Warfarin; Young Adult | 2016 |
Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Bronchopulmonary Dysplasia; Cardiac Catheterization; Child; Child, Preschool; Chronic Disease; Female; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Male; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2008 |
Chronic thromboembolic pulmonary hypertension as a cause of dyspnoea in an older patient with a complex history.
Topics: Antihypertensive Agents; Bosentan; Chronic Disease; Dyspnea; Endarterectomy; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Embolism; Sulfonamides; Tomography, Spiral Computed | 2009 |
Improved survival in patients with inoperable chronic thromboembolic pulmonary hypertension.
Topics: Acid-Base Equilibrium; Aged; Antihypertensive Agents; Blood Gas Analysis; Bosentan; Cardiac Output; Chronic Disease; Drug Therapy, Combination; Exercise Test; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Oxygen Consumption; Oxygen Inhalation Therapy; Piperazines; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Thromboembolism; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2013 |
Effect of endothelin receptor antagonist bosentan on chronic hypoxia-induced inflammation and chemoafferent neuron adaptation in rat carotid body.
Topics: Acid Sensing Ion Channels; Adaptation, Physiological; Animals; Antihypertensive Agents; Bosentan; Carotid Body; Cell Movement; Chemokine CCL2; Chemoreceptor Cells; Chronic Disease; Endothelin-1; Gene Expression; Hypoxia; Inflammation; Interleukin-1; Interleukin-1beta; Leukocyte Common Antigens; Macrophages; Rats; Receptor, Endothelin A; Sulfonamides; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2012 |
Endothelin receptor blockade and exacerbation of heart failure.
Topics: Animals; Bosentan; Chronic Disease; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Heart; Heart Failure; Humans; Myocardial Contraction; Phenylpropionates; Pyrimidines; Rats; Receptor, Endothelin A; Sulfonamides; Vascular Resistance; Water-Electrolyte Balance | 2003 |
Role of endothelin-1 on the enhanced carotid body activity induced by chronic intermittent hypoxia.
Topics: Animals; Bosentan; Carotid Body; Cats; Chronic Disease; Electrophysiology; Endothelin Receptor Antagonists; Endothelin-1; Hypoxia; Immunohistochemistry; In Vitro Techniques; Male; Sulfonamides | 2006 |
Long-term bosentan in chronic thromboembolic pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Chronic Disease; Exercise Tolerance; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Male; Prospective Studies; Sulfonamides; Thromboembolism; Treatment Outcome; Ventricular Function, Right | 2007 |
Bosentan in Eisenmenger syndrome and chronic thromboembolic pulmonary hypertension.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Chronic Disease; Down Syndrome; Echocardiography, Doppler; Eisenmenger Complex; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Pulmonary Embolism; Sulfonamides; Treatment Outcome | 2006 |
[Chronic pulmonary thromboembolism revealing beta-thalassemia intermedia after splenectomy].
Topics: Antihypertensive Agents; beta-Thalassemia; Bosentan; Chronic Disease; Humans; Iron Overload; Male; Middle Aged; Pulmonary Embolism; Splenectomy; Sulfonamides; Treatment Outcome | 2006 |
Severe pulmonary hypertension due to chronic echinococcal pulmonary emboli treated with targeted pulmonary vascular therapy and hepatic resection.
Topics: Adult; Antihypertensive Agents; Bosentan; Chronic Disease; Echinococcosis, Hepatic; Echinococcosis, Pulmonary; Epoprostenol; Hepatectomy; Humans; Hypertension, Pulmonary; Male; Pulmonary Artery; Pulmonary Embolism; Sulfonamides; Thoracic Surgery, Video-Assisted; Vena Cava, Inferior | 2007 |
Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats.
Topics: Animals; Bosentan; Chronic Disease; Endothelin Receptor Antagonists; Endothelins; Hemodynamics; Hypertension, Pulmonary; Hypoxia; In Vitro Techniques; Male; Rats; Rats, Wistar; Sulfonamides | 1995 |
Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan).
Topics: Animals; Blood Pressure; Bosentan; Chronic Disease; Cilazapril; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Male; Rats; Rats, Wistar; Sulfonamides | 1994 |
Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Cardiac Volume; Chronic Disease; Collagen; Consciousness; Coronary Vessels; Cyclic GMP; Echocardiography; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Heart Failure; Heart Ventricles; Male; Myocardial Infarction; Myocardium; Norepinephrine; Pressure; Protein Precursors; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Survival Analysis; Ventricular Function, Left | 1997 |
Nitric oxide and endothelin in acute hypoxic pulmonary vasoconstriction and adaptation to chronic hypoxia.
Topics: Acclimatization; Acute Disease; Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Chronic Disease; Endothelium, Vascular; Hypoxia; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Sulfonamides; Vasoconstriction | 1997 |
Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Bosentan; Chronic Disease; Culture Techniques; Disease Models, Animal; Dogs; Endothelin-1; Female; Hemodynamics; Hypertension, Pulmonary; Immunohistochemistry; Lung; Male; Probability; Pulmonary Artery; Pulmonary Circulation; Pulmonary Embolism; Reference Values; Sulfonamides; Tomography, Emission-Computed; Vascular Resistance | 2000 |
Endothelin receptor blockade in congestive heart failure.
Topics: Acute Disease; Antihypertensive Agents; Bosentan; Chronic Disease; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Exercise Tolerance; Heart Failure; Hemodynamics; Humans; Phenylpropionates; Pyridines; Pyrimidines; Sulfonamides; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2001 |